Antengene Approved to Launch XPO1 Inhibitor for Multiple Myeloma
publication date: Dec 17, 2021
Shanghai Antengene announced that Xpovio® (selinexor), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE), was approved in China for relapsed or refractory multiple myeloma. It is China's first approved XPO1 inhibitor and Antengene's first approved product. The conditional approval is for second-line therapy in combination with dexamethasone. In 2018, Antengene in-licensed China rights to four novel oral drug candidates including Xpovio® from Boston's Karyopharm in an $162 million agreement. More details....
Stock Symbol: (NSDQ: KPTI)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.